Daicel-evonik Ltd.
USPTO PatentsView assignee record - 21 granted patents across 25 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C08L (Compositions OF Macromolecular Compounds).
The verdict
According to USPTO PatentsView, Daicel-evonik ranks #13,939 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 25 technology areas.
- #13,939
- of 49,997 US assignees by volume
- Top 27%
- by Innovation Score (43.8/100)
- 11.4
- avg claims per patent
- +33%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R13939 · Foreign Corporation #13,939 · 21 grants
GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-UP · BOOK-FULL
- GRANTS-SMALL 21 grants
- MID-PACK #13,939/49,997
- PHOTO-FINISH Curiteva
- CPC-FOCUS C08L · 25 areas
- INNOV-PAR 43.8/100
- CLAIMS-PAR 11.4 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-UP +33% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Curiteva, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Daicel-evonik’s 43.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Daicel-evonik
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Daicel-evonik · this assignee
Daicel-evonik · this assignee
44 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Daicel-evonik's Innovation Score is 43.8/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Daicel-evonik?
Each dot is one of Daicel-evonik’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Daicel-evonik’s own 11.4 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Daicel-evonik's grants concentrate
Daicel-evonik Ltd. is a focused PatentsView assignee: 25 CPC subclasses with 61.9% of grants classified under C08L (Compositions OF Macromolecular Compounds). Peak complete grant year is 2024 (6 grants) versus a trough of 1 in 2015. By volume, Daicel-evonik sits between Curiteva, Inc. and Dehn SE + Co KG.
Daicel-evonik's three-year grant acceleration
Daicel-evonik Ltd. shows 9 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Daicel-evonik's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Curiteva
Curiteva, Inc.
21 patents
- Custom-pak
Custom-Pak, Inc.
21 patents
- Cytek Biosciences
Cytek Biosciences, Inc.
21 patents
- DA International
DA International, Inc.
21 patents
- Daizo
Daizo Corporation
21 patents
- Data Systems
Data Systems Co., Ltd.
21 patents
- Datometry
Datometry, Inc.
21 patents
- Dehn SE + KG
Dehn SE + Co KG
21 patents
- Daicel-evonik ◀
Daicel-evonik Ltd.
21 patents
What this shows Daicel-evonik holds 21 patents at rank #13,939, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Daicel-evonik
By rank, the assignees closest to #13,939 in granted patent volume.
- Curiteva, Inc. #13,935 · 21 patents
- Custom-Pak, Inc. #13,936 · 21 patents
- Cytek Biosciences, Inc. #13,937 · 21 patents
- DA International, Inc. #13,938 · 21 patents
- Daizo Corporation #13,940 · 21 patents
- Data Systems Co., Ltd. #13,941 · 21 patents
- Datometry, Inc. #13,942 · 21 patents
- Dehn SE + Co KG #13,943 · 21 patents
Leaders in C08L (Compositions OF Macromolecular Compounds)
Other assignees with the most granted patents in Daicel-evonik's primary technology class.
Daicel-evonik's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
44 Top 27% higher than 73% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 4.8% |
| 2016 | 2 | 9.5% |
| 2017 | 1 | 4.8% |
| 2018 | 1 | 4.8% |
| 2019 | 4 | 19.0% |
| 2020 | 1 | 4.8% |
| 2021 | 2 | 9.5% |
| 2022 | 1 | 4.8% |
| 2023 | 2 | 9.5% |
| 2024 | 6 | 28.6% |
Which technologies does Daicel-evonik Ltd. patent most?
Top 15 of 25 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Daicel-evonik Ltd.'s patent record in context - here's where to go next.
- Daicel-evonik Ltd.'s lead technology class is C08L (Compositions OF Macromolecular Compounds), 61.9% of its portfolio - see every assignee active in that class. Explore C08L
- Ranked #13,939 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Daicel-evonik Ltd. against Curiteva, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 43.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.